ASQ group

(n = 35)

Non-ASQ group

(n = 35)

p value

Demographics

Male, n (%)

30 (85.7%)

27 (77.1%)

0.54

Age (years)

73 ± 4.2

73 ± 4.5

0.65

Height (cm)

165

164

0.64

Body weight (kg)

63

62

0.23

BMI (kg/m²)

24

22

0.23

Cause of HF

Ischemic heart disease, n (%)

13 (37.1%)

10 (26.6%)

0.61

Nonischemic heart disease, n (%)

19 (54.3%)

15 (42.9%)

0.47

Valvular, n (%)

1 (2.9%)

1 (2.9%)

> 0.99

2^nd CM, n (%)

1 (2.9%)

4 (11.4%)

0.36

Other, n (%)

1 (2.9%)

5 (14.3%)

0.20

Medical history

Atrial fibrillation, n (%)

8 (22.9%)

12 (34.3%)

0.43

Hypertension, n (%)

12 (34.3%)

16 (45.7%)

0.46

Diabetes, n (%)

10 (28.6%)

8 (22.9%)

0.78

Dialysis, n (%)

2 (5.7%)

0 (0%)

0.49

Clinical

NYHA class

II, n (%)

20 (57.1%)

23 (65.7%)

0.62

≧III, n (%)

15 (42.9%)

12 (34.3%)

0.62

CRTD, n (%)

33 (94.3%)

30 (85.7%)

0.43

Primary prevention, n (%)

27 (77.1%)

29 (82.9%)

0.77

Heart rate, beats/min

70 ± 20

72 ± 21

0.17

QRS width (ms)

154 ± 23

152 ± 17

0.75

LBBB, n (%)

30 (85.7%)

28 (80.0%)

0.75

LVEF, %

29 ± 9.5

29 ± 8.2

0.74

LVEDV, (ml)

135 ± 10.5

150 ± 9.5

0.17

LVESV, (ml)

93 ± 8.3

99 ± 11.2

0.17

Creatinine, (mg/dl)

1.37 ± 0.76

1.59 ± 0.66

0.40

BNP, (pg/ml)

406 ± 182

521 ± 178

0.89

Medications

ACEI/ARB

17 (48.6%)

19 (54.3%)

0.81

ARNI

12 (34.3%)

8 (22.9%)

0.43

Beta-blockers

32 (91.4%)

33 (94.3%)

> 0.99

MRA

14 (40.0%)

22 (62.9%)

0.09

SGLT2-I

7 (20.0%)

1 (2.9%)

0.06

Diuretics

16 (45.7%)

11 (31.4%)

0.33

Amiodarone

5 (14.3%)

7 (20.0%)

0.75